188 related articles for article (PubMed ID: 17556623)
1. Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis.
Llanos-Cuentas A; Echevarria J; Seas C; Chang E; Cruz M; Alvarez E; Rosales E; Campos P; Bryceson A
Am J Trop Med Hyg; 2007 Jun; 76(6):1128-31. PubMed ID: 17556623
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
Soto J; Hernandez N; Mejia H; Grogl M; Berman J
Clin Infect Dis; 1995 Jan; 20(1):47-51. PubMed ID: 7727669
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
Krolewiecki AJ; Romero HD; Cajal SP; Abraham D; Mimori T; Matsumoto T; Juarez M; Taranto NJ
Am J Trop Med Hyg; 2007 Oct; 77(4):640-6. PubMed ID: 17978064
[TBL] [Abstract][Full Text] [Related]
5. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
[TBL] [Abstract][Full Text] [Related]
6. Drug hypersensitivity syndrome induced by meglumine antimoniate.
Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA
Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253
[TBL] [Abstract][Full Text] [Related]
7. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
Soto J; Fuya P; Herrera R; Berman J
Clin Infect Dis; 1998 Jan; 26(1):56-8. PubMed ID: 9455509
[TBL] [Abstract][Full Text] [Related]
8. Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil.
Araujo-Melo MH; Meneses AM; Schubach AO; Moreira JS; Conceição-Silva F; Salgueiro MM; Pimentel MI; Araújo-Silva M; Oliveira RV; Carmo CN; Valete-Rosalino CM
J Laryngol Otol; 2010 Oct; 124(10):1056-60. PubMed ID: 20537206
[TBL] [Abstract][Full Text] [Related]
9. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Bolivian mucosal leishmaniasis with miltefosine.
Soto J; Toledo J; Valda L; Balderrama M; Rea I; Parra R; Ardiles J; Soto P; Gomez A; Molleda F; Fuentelsaz C; Anders G; Sindermann H; Engel J; Berman J
Clin Infect Dis; 2007 Feb; 44(3):350-6. PubMed ID: 17205440
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
[TBL] [Abstract][Full Text] [Related]
12. Back from the Peace Corps--with skin lesions from South America.
Sorci JJ; Cordova X; Usatine RP
J Fam Pract; 2003 Jul; 52(7):531-6. PubMed ID: 12884834
[No Abstract] [Full Text] [Related]
13. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
[TBL] [Abstract][Full Text] [Related]
14. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
Bermúdez H; Rojas E; Garcia L; Desjeux P; Dujardin JC; Boelaert M; Chappuis F
Ann Trop Med Parasitol; 2006 Oct; 100(7):591-600. PubMed ID: 16989685
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of intralesional meglumine antimoniate in the treatment of mucosal leishmaniasis of the Old World.
Zaraa I; Karoui S; Osman AB
J Dermatol; 2012 Feb; 39(2):201-3. PubMed ID: 21950659
[No Abstract] [Full Text] [Related]
16. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
Salmanpour R; Handjani F; Nouhpisheh MK
J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
[TBL] [Abstract][Full Text] [Related]
17. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
18. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
19. [The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis].
Sampaio RN; de Paula CD; Sampaio JH; Furtado Rde S; Leal PP; Rosa TT; Rodrigues ME; Veiga JP
Rev Soc Bras Med Trop; 1997; 30(6):457-63. PubMed ID: 9463192
[TBL] [Abstract][Full Text] [Related]
20. [Open therapeutic study with aminosidine sulfate in mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis].
Romero GA; Lessa HA; Macêdo VO; Carvalho EM; Barral A; Magalhães AV; Orge MG; Abreu MV; Marsden PD
Rev Soc Bras Med Trop; 1996; 29(6):557-65. PubMed ID: 9011880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
